Curated News
By: NewsRamp Editorial Staff
April 15, 2026
Polyrizon Secures $3.5M Funding for Nasal Shield Biotech Innovation
TLDR
- Polyrizon secured $3.5 million in funding, providing capital to advance its intranasal protective technology and potentially gain an edge in biotech innovation.
- Polyrizon raised $3.5 million through a direct offering and private placement, selling units at $9.00 each to fund working capital and corporate operations.
- Polyrizon's nasal spray technology creates a protective barrier against viruses and allergens, aiming to improve public health and reduce disease transmission.
- Polyrizon is developing a nasal hydrogel that acts as a biological mask, using natural building blocks to trap viruses before they infect tissue.
Impact - Why it Matters
This development matters because Polyrizon's intranasal protective technology represents a potentially transformative approach to respiratory health protection. In a world increasingly concerned about viral transmission and airborne allergens, a non-invasive nasal barrier could offer significant advantages over traditional masks and medications. The funding enables continued research and development of what essentially functions as a 'biological mask' - technology that could provide continuous protection without the discomfort and limitations of physical face coverings. For investors, this represents an opportunity in the growing biotech sector focused on preventive healthcare solutions. For the general public, successful development could lead to more convenient, effective protection against respiratory illnesses and allergens, potentially reducing healthcare costs and improving quality of life for millions who suffer from seasonal allergies or are at risk of viral infections. The company's additional work on drug delivery through nasal sprays could also revolutionize how medications are administered, making treatments more targeted and efficient.
Summary
Polyrizon Ltd. (NASDAQ: PLRZ), a pre-clinical-stage biotechnology company, has successfully secured approximately $3.5 million in gross proceeds through a registered direct offering and concurrent private placement with a single institutional investor. The financial transactions involved the sale of 388,888 units or pre-funded units at a combined price of $9.00 per unit, which included ordinary shares or pre-funded warrants and common warrants, with additional warrants issued in the private placement. Aegis Capital Corp. served as the exclusive placement agent for these deals, and the company intends to allocate the proceeds toward working capital and general corporate purposes, bolstering its operational capabilities during this critical development phase.
At the core of Polyrizon's innovative approach is its proprietary Capture and Contain™ (C&C) hydrogel technology, which forms the basis of its intranasal protective solutions. This technology, delivered via nasal sprays, creates a thin hydrogel-based shield containment barrier in the nasal cavity, designed to act as a "biological mask" by preventing viruses and allergens from contacting nasal epithelial tissue. The company is further advancing its C&C hydrogel technology to enhance bioadhesion and prolonged retention for intranasal drug delivery, while also developing an earlier-stage pre-clinical technology called Trap and Target™ (T&T) focused on nasal delivery of active pharmaceutical ingredients (APIs). For more detailed information, readers can view the full press release through the provided link.
The news was disseminated by TechMediaWire (TMW), a specialized communications platform within the Dynamic Brand Portfolio @ IBN that focuses on technology-driven companies. TMW provides comprehensive services including access to wire solutions via InvestorWire, article and editorial syndication to over 5,000 outlets, enhanced press release distribution, social media distribution through IBN's network, and tailored corporate communications solutions. This platform helps companies like Polyrizon reach a wide audience of investors, influencers, consumers, and journalists, ensuring maximum visibility in today's crowded information landscape. For those interested in staying updated on technology news, TMW offers SMS alerts by texting "TECH" to 888-902-4192 (U.S. Mobile Phones Only).
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Polyrizon Secures $3.5M Funding for Nasal Shield Biotech Innovation
